Advances in Blood-based Biomarkers and Disease Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease

EVENT Summary

Dates

Saturday, August 3, 2024, 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT

Location

Virtual

Target Audience

Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.

Format

Zoom Webinar

Credits

1.50 / AMA PRA Category 1 Credit(s)^TM
1.50 / ANCC Contact Hours

Cost

Free

Program Description

Click to Go to the Event Registration

This webinar provides an up-to-date, evidence-based information on pathophysiology, biomarkers, and disease-modifying drugs in treating Alzheimer’s disease (AD).

Agenda

• Discuss the blood-based biomarkers in diagnosing early-stage Alzheimer’s disease (AD) and its utility in the prevention – Gary Small, MD
• Discuss clinical trial data on safety-efficacy profiles of approved and investigational disease-modifying anti-amyloid antibody therapies in managing early AD – Paul Schulz MD

Intended Audience

Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.

Commercial Supporter

Supported by an educational grant from Eisai, Inc.

Learning Objectives

• Summarize the pathophysiology and the clinical presentation of Alzheimer’s disease (AD).
• Assess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.
• Identify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.

Accredited Providers

Amedco and MedNet have collaborated to design and execute this activity.

      

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.

Physicians (ACCME) Credit

Designation Statement

Amedco LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit

Designation Statement

Amedco LLC designates this activity for a maximum of 1.50 ANCC contact hours.

Additional Credit Information

Physician Assistants
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit^TM from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.5 hours.

Disclosures of Relationships with Ineligible Companies Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

Planners’ and Managers’ Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

All relevant relationships have been reviewed and mitigated.

Kamatham A. Naidu, PhD (MedNet), has no relevant financial relationships to disclose.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Justin Kaiser (Amedco) has no relevant financial relationships to disclose.

Off-Label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Faculty

Gary Small, MD
Chair of Psychiatry, Hackensack University Medical Center
Behavioral Health Physician-in-Chief
Hovnanian Foundation Chair
Hackensack Meridian Health
Professor and Chair of Psychiatry & Behavioral Health
Hackensack Meridian School of Medicine
Hackensack, NJ

Paul Schulz, MD
Rick McCord Professor in Neurology,
Umphrey Family Professor of Neurodegenerative Disorders,
Director, Memory Disorders and Dementia Clinic,
Director, Neuropsychiatry and Behavioral Neurology Fellowship,
The McGovern Medical School of UTHealth
Houston, TX

Instructions/Technical Requirements

• A desktop or laptop computer or a mobile device with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.
• Times in the portal adjust to your computer; however, some browsers have a separate time zone adjustment.
• For the best viewing experience, we recommend the following browsers: Chrome, Firefox, and Safari. For attendees viewing on Internet Explorer 11, you may experience lags in streaming. To maximize your attendee hub experience, we recommend you not sign in through your company assigned VPN.
• Ensure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.

Cost

Complimentary

Contact

Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net